Why it matters now
Generic drug shortages have become a persistent and growing challenge, leading to significant disruptions in patient care, increased costs, and compromised public health. These shortages stem from complex factors including supply chain vulnerabilities, manufacturing issues, and economic pressures on generic producers. Identifying which molecules are most vulnerable is critical for building resilient supply chains, developing contingency plans, and safeguarding access to essential, affordable medicines.
Who is exposed
Generic drug manufacturers face reputational damage, lost revenue, and potential regulatory penalties from supply failures. Hospitals and pharmacies experience operational disruptions, increased costs from alternative sourcing, and compromised patient care. Healthcare systems bear the burden of managing these shortages, impacting patient outcomes and trust. Patients may face delayed or suboptimal treatments, affecting health outcomes.
Most relevant for: Head of Supply Chain, Chief Procurement Officer, Chief Medical Officer
What this Viewpoint covers
- Which generic drug molecules have a history of frequent or prolonged shortages?
- What are the common underlying causes of supply failure for these high-risk molecules?
- Which manufacturing sites or regions are critical single points of failure for essential generics?
- How do regulatory actions and quality issues contribute to generic drug shortages?
- What is the market concentration among manufacturers for high-risk generic drugs?
Signals to watch
- Public alerts from regulatory bodies regarding drug supply disruptions.
- Reports on manufacturing plant inspections and quality control issues.
- Changes in the number of active manufacturers for specific generic drugs.
- Geopolitical events impacting key raw material suppliers.
Decisions it supports
- Develop diversified sourcing strategies for critical generic drugs.
- Implement inventory management and buffer stock policies.
- Inform advocacy efforts for supply chain resilience policies.
How it is built
Prepared after your order from dated public sources - such as generic pharmaceuticals filings and announcements, regulatory records, trials, patents and trade data, where relevant - and our market model. Reported facts are cited, estimates are labelled and our assessment is marked as such, following our research method. You receive our verdict, the evidence, who is exposed, the signals to watch and recommended actions, within 24 hours.
Questions
Why is it important to identify generic drugs at risk of shortage?
Proactive identification of at-risk generic drugs allows hospitals, pharmacies, and healthcare systems to implement mitigation strategies before a shortage occurs. This ensures continuity of patient care, minimizes operational disruptions, and helps manage costs by avoiding expensive alternative treatments. It's crucial for maintaining public health and trust.
What factors contribute to generic drug shortages?
Shortages often arise from a combination of factors, including manufacturing quality issues, raw material supply disruptions, unexpected increases in demand, limited number of manufacturers for a specific drug, and economic pressures that make certain drugs unprofitable to produce. Geopolitical events and natural disasters can also play a significant role.
How can this Viewpoint help my supply chain management?
This Viewpoint provides insights into specific vulnerabilities within the generic drug supply chain. It helps you identify critical molecules and their associated risks, allowing you to develop more robust sourcing strategies, evaluate supplier diversity, and implement proactive inventory management. This strengthens your overall supply chain resilience and reduces the impact of future shortages.